Apellis Pharmaceuticals (APLS) said Monday that Australia's Therapeutic Goods Administration approved Syfovre for the every-other-month treatment of geographic atrophy in adults with age-related macular degeneration resulting in vision loss.
The decision was supported by 24-month data from phase 3 studies, which showed that both monthly and every-other-month use of the treatment reduced GA progression and was generally well tolerated, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。